Dyne Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 2, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 2, 2026
DYN$17.92-3.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
| Common Stock · AdditionalPaid-InCapital · Accumulated Other Comprehensive Gain (Loss) · AccumulatedDeficit · Stockholders’Equity | ||||||
|---|---|---|---|---|---|---|
| (in thousands, except share data) · Shares · Amount | ||||||
| Balance at January 1, 2023 | 55,636,505 | $6 | $649,502 | $(571) | $(396,573) | $252,364 |
| Issuance of common stock in at-the-market offering, net of issuance costs of $1.8 million | 4,509,063 | — | 52,369 | — | — | 52,369 |
| Exercise of stock options | 832,906 | — | 1,953 | — | — | 1,953 |
| Stock-based compensation | — | — | 19,972 | — | — | 19,972 |
| Vesting of restricted stock units | 490,269 | — | — | — | — | — |
| Unrealized gains on marketable securities | — | — | — | 571 | — | 571 |
| Net loss | — | — | — | — | (235,937) | (235,937) |
| Balance at December 31, 2023 | 61,468,743 | 6 | 723,796 | — | (632,510) | 91,292 |
| Issuance of common stock in public offering, net of issuance costs of $44.3 million | 31,797,500 | 3 | 675,177 | — | — | 675,180 |
| Issuance of common stock in at-the-market offering, net of issuance costs of $3.3 million | 3,800,465 | 1 | 97,870 | — | — | 97,871 |
| Exercise of stock options | 4,181,133 | — | 37,043 | — | — | 37,043 |
| Stock-based compensation | — | — | 45,864 | — | — | 45,864 |
| Vesting of restricted stock units | 1,070,788 | — | — | — | — | — |
| Unrealized gains on marketable securities | — | — | — | 6 | — | 6 |
| Net loss | — | — | — | — | (317,418) | (317,418) |
| Balance at December 31, 2024 | 102,318,629 | 10 | 1,579,750 | 6 | (949,928) | 629,838 |
| Issuance of common stock in public offering, net of issuance costs of $39.0 million | 49,706,337 | 5 | 593,528 | — | — | 593,533 |
| Issuance of common stock in at-the-market offering, net of issuance costs of $4.4 million | 10,660,159 | 1 | 140,652 | — | — | 140,653 |
| Exercise of stock options | 990,926 | — | 7,999 | — | — | 7,999 |
| Stock-based compensation | — | — | 45,851 | — | — | 45,851 |
| Vesting of restricted stock units | 1,274,489 | — | — | — | — | — |
| Unrealized gains on marketable securities | — | — | — | 469 | — | 469 |
| Net loss | — | — | — | — | (446,214) | (446,214) |
| Balance at December 31, 2025 | 164,950,540 | $16 | $2,367,780 | $475 | $(1,396,142) | $972,129 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.